Louisiana State University

LSU Digital Commons
Faculty Publications

School of Animal Sciences

1-1-2000

Safety and efficacy of Brucella abortus strain RB51 vaccine in
captive pregnant elk
Terry J. Kreeger
Wyoming Game and Fish Department

Michael W. Miller
USDA APHIS National Wildlife Research Center

Margaret A. Wild
USDA APHIS National Wildlife Research Center

Philip H. Elzer
LSU Agricultural Center

Steven C. Olsen
USDA ARS National Animal Disease Center

Follow this and additional works at: https://digitalcommons.lsu.edu/animalsciences_pubs

Recommended Citation
Kreeger, T., Miller, M., Wild, M., Elzer, P., & Olsen, S. (2000). Safety and efficacy of Brucella abortus strain
RB51 vaccine in captive pregnant elk. Journal of Wildlife Diseases, 36 (3), 477-483. https://doi.org/
10.7589/0090-3558-36.3.477

This Article is brought to you for free and open access by the School of Animal Sciences at LSU Digital Commons.
It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital Commons.
For more information, please contact ir@lsu.edu.

Journal of Wildlife Diseases, 36(3), 2000, pp. 477–483
䉷 Wildlife Disease Association 2000

SAFETY AND EFFICACY OF BRUCELLA ABORTUS STRAIN RB51
VACCINE IN CAPTIVE PREGNANT ELK
Terry J. Kreeger,1,5 Michael W. Miller,2 Margaret A. Wild,2 Philip H. Elzer,3 and
Steven C. Olsen4
Wyoming Game and Fish Department, 2362 Highway 34, Wheatland, Wyoming 82201, USA
Colorado Division of Wildlife, Wildlife Research Center, 317 West Prospect Road,
Fort Collins, Colorado 80526-2097, USA
3
Department of Veterinary Science, Louisiana State University Agricultural Center,
Baton Rouge, Louisiana 70803, USA
4
Zoonotic Disease Research Unit, National Animal Disease Center, Agricultural Research Service,
U.S. Department of Agriculture, 2300 Dayton Ave., Ames, Iowa 50010, USA
5
Corresponding author (e-mail: tekreege@wyoming.com)
1
2

INTRODUCTION

Brucellosis is a zoonotic disease of domestic and wild ungulates (Hunter and
Kreeger, 1998). Brucella spp. are faculative intracellular bacteria causing chronic
disease that usually persists for life. Mortality in adults is rare, but mortality of offspring may be high in a recently-infected
herd. Infection of the female reproductive
tract often results in abortion (Enright,
1990).
For economic and health purposes, a
cooperative state/federal brucellosis eradication program began in 1934 with the
goal of controlling, then eliminating, brucellosis in domestic cattle in the United
States. The majority of states are now classified as brucellosis-free (Cheville et al.,
1998). However, brucellosis is endemic in
elk (Cervus elaphus) and bison (Bison bison) in the Greater Yellowstone Area
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(GYA) (Tunnicliff and Marsh, 1935), an
ecosystem encompassing Yellowstone National Park, Grand Teton National Park,
and surrounding areas in Wyoming, Montana, and Idaho (USA). The presence of
brucellosis in wildlife creates a conflict
with the national goal of eradication.
Brucellosis vaccines are comprised of
living, mutant Brucella sp. organisms that
infect the host, but are less pathogenic
than the parent strain while providing prolonged immunity. Two licensed vaccines
are B. abortus strain 19 and strain RB51.
Strain 19 has been used for decades in cattle and free-ranging elk; however, it induces production of antibodies to the lipopolysaccharide (LPS) O-side chain that are
detected in some serologic tests for brucellosis (Stevens et al., 1995). Thus, differentiation between serologic responses following infection and vaccination may be
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ABSTRACT: Brucella abortus strain RB51 is a laboratory-derived rough mutant of virulent B.
abortus strain 2308 used as a vaccine because it induces antibodies that do not react on standard
brucellosis serologic tests. Strain RB51 vaccine was evaluated in pregnant captive elk (Cervus
elaphus) to determine (1) if it induced abortion and (2) if it protected against abortion following
subsequent challenge. The time period of this study (February–June, 1998) was similar to field
conditions where elk are vaccinated and possibly exposed to B. abortus. Fourteen elk were randomly and equally divided into vaccinated and control groups. The vaccinated group was vaccinated intramuscularly with 1.03 ⫻ 1010 colony-forming units (CFU) of strain RB51 and seroconverted postvaccination. Antibodies to strain RB51 were detected by a modification of an existing
dot-blot assay. Both groups were challenged 40 days postvaccination with 9.8 ⫻ 106 CFU of B.
abortus strain 2308 administered intraconjunctivally. The first abortion occurred 38 days postchallenge. Abortion occurred in all control elk and in five of seven vaccinated elk 5 to 12 wk
postchallenge (P ⫽ 0.23). Mixed strain RB51 and 2308 infections were present in fetuses and
vaginas from the vaccinated group whereas only strain 2308 was cultured from control group
fetuses and vaginal swabs. Further evaluation of strain RB51 will be necessary to determine if it
will be safe and efficacious in free-ranging pregnant elk.
Key words: Abortion, Brucella abortus, Cervus elaphus, dot-blot assay, elk, strain RB51, vaccination.
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MATERIALS AND METHODS

This study was from February–June 1998 at
the Colorado Division of Wildlife’s (CDW)

Foothills Wildlife Research Facility (Fort Collins, Colorado, USA; 40⬚35⬘N, 105⬚10⬘W).
Fourteen, captive, Brucella seronegative, adult
female Rocky Mountain elk were used in this
study; nine were from the CDW facilities, two
were transferred from WGFD research facilities, and three from Idaho Department of Fish
and Game facilities. All elk were fed alfalfa hay
cubes supplemented with grass hay and a highenergy pelleted supplement (Baker et al.,
1998). Water and a trace mineral block were
provided ad libitum.
All elk were diagnosed pregnant using pregnancy-specific protein analysis (Biotracking,
Moscow, Idaho, USA), then randomly and
equally divided into vaccinated and control
groups. All elk were examined for Brucella antibodies using four standard serologic tests
(MacMillan, 1990) and determined to be negative prior to initiation of the test. Vaccinated
and control groups were housed separately in
4 ha pastures.
On February 26, 1998, the vaccinated group
was inoculated intramuscularly with 1.03 ⫻
1010 CFU of strain RB51 vaccine (Colorado Serum Co., Denver, Colorado, USA) administered in the hindquarters. The vaccine dosage
was determined by standard plate counts on
tryptose agar plus 5% bovine serum. The control group was given sterile saline administered
similarly. Elk were observed daily after vaccination for signs of morbidity or abortion.
On 7 April 1998 (40 days postvaccination),
all elk were challenged via the conjunctival sac
with 9.8 ⫻ 106 CFU of B. abortus strain 2308,
an established virulent strain in cattle (Elzer et
al., 1998). The inoculum, prepared as described in Elzer et al. (1994) and diluted in
sterile saline, was administered by dropping 50
l in each eye using a Gilson pipetman P100.
The challenge dose was verified by serial dilutions and plating as above with the vaccine
dose. Elk were lightly sedated with 40–80 mg
xylazine hydrochloride prior to inoculation. The
time period of the test was chosen because it
represented natural conditions where elk on
feedgrounds would normally be vaccinated
then possibly exposed to Brucella-induced
abortions (Herriges et al., 1989).
Sera collected at vaccination and at challenge
were tested for antibodies to strain RB51 using
a dot blot assay (Olsen et al., 1997) modified
for use in elk. Samples were evaluated without
knowledge of vaccination status. The secondary
antibody used in this assay was determined by
absorption of elk sera on 0.45 m nitrocellulose
(Schleicher and Schuell Inc, Keene, New
Hampshire, USA) and screening with the following peroxidase-conjugated antibodies: rabbit anti-bovine IgG-heavy and light chain spe-
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difficult. Strain RB51 is a laboratory-derived rough mutant of virulent B. abortus
strain 2308. It lacks most of the antigenic
LPS O-side chain (Schurig et al., 1991)
and it does not induce antibodies that react in particle concentration fluorescence
immunoassay, card, tube agglutination, or
complement fixation tests (Stevens et al.,
1994). Because of this, strain RB51 has become the preferred vaccine for cattle and
it may become the preferred vaccine for
wildlife.
The Wyoming Game and Fish Department (WGFD; Cheyenne, Wyoming,
USA) has vaccinated thousands of elk on
feedgrounds in the GYA with a reduceddose strain 19 vaccine delivered remotely
by biobullet (Herriges et al., 1989) and a
significant decrease in seropositivity before
and after 10 years of vaccination has been
documented (S. Smith, pers. comm.). Vaccination with strain RB51 would allow serologic differentiation of vaccinated elk
from those exposed to field strain B. abortus.
Calfhood vaccination against brucellosis
is usually preferred in domestic and wild
species because adult vaccination with
strain 19 may result in abortion (Davis et
al., 1991; Cheville et al., 1996; Palmer et
al., 1996). However, preliminary studies
have found that RB51 vaccination of pregnant elk resulted in few or no abortions
(WGFD, unpubl. data). This finding suggested that vaccination of adult elk on
feedgrounds could be an effective means
of reducing brucellosis-induced abortions
with subsequent reduction of the disease
in elk populations. In addition, vaccination
of adults would enhance the protection of
calfhood vaccination and increase the efficacy of strain RB51. Thus, we examined
the safety and efficacy of strain RB51 vaccine to protect elk against abortion under
conditions that would mimic potential field
applications. Additionally, we developed a
modified dot-blot assay to measure antibodies to strain RB51 in elk.
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vious studies (S. Olsen, unpubl. data), was
found to react against B. abortus strain RB51
in the dot blot assay. Although goat anti-serum
against strain RB51 would have been ideal, this
was not available at the time of this study.
Wells to which no serum was added served
as negative controls for each assay. Elk sera was
not used for negative controls because sera
were evaluated blindly. Because the vaccination
status of a sample was unknown, using elk serum as a negative control was not possible.
Thirty l of each serum dilution and positive
controls were added to separate wells of the
microfiltration unit. Following a 30-min incubation, the nitrocellulose was dried by vacuum
and washed five times with 100 l per well of
Tris-NaCl-Tween. The peroxidase-conjugated
secondary antibody was diluted 1/2,000 in TrisFG and a 100 l aliquot added to all wells.
After 30 min incubation, the wells were washed
five times with Tris-NaCl-Tween and dried for
30 sec under vacuum. The nitrocellulose was
removed from the microfiltration unit and incubated for 10 min in Tris-NaCl containing 0.5
mg of 4-chloro-1-napthol/ml and 0.15% H2O2
(Sigma Chemical Co, St Louis, Missouri, USA).
Membranes were dried in the dark for 12 hr at
22 C before interpretation. Results were expressed as the highest serum titer that produced a visible color reaction that was interpreted to be no less than 50% of the intensity
of the color reaction produced by the positive
control sera.
Following challenge, elk were observed
twice daily for abortion or other indications of
reaction to the challenge dose. Calving was assisted if signs of labor exceeded 12 hr or if an
abnormal presentation was observed. Aborted
fetuses were collected immediately and frozen,
then necropsied and tissues cultured at later
date. Following normal parturition, calves were
observed for ⱖ10 days to assess health and fitness after which they were blood sampled for
serology, euthanized, necropsied, and tissues
cultured. Vaginal swabs (Culturette,娂 Becton
Dickinson, Cockeysville, Maryland, USA) were
collected and placed in modified Amies with
charcoal or modified Stuart’s media, frozen,
and cultured. Upon abortion or delivery, adult
elk were blood sampled for antibodies against
strains 2308 and RB51. Seroconversion to
strain 2308 was determined using standard
plate agglutination, standard tube, rivanol, and
complement fixation tests. Titers were considered positive based on criteria established by
Morton et al. (1981). When possible, milk samples were also taken and cultured.
The primary culture medium consisted of
Brucella agar (Difco Laboratories, Detroit,
Michigan, USA) with the addition of 7,500 I.U.
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cific; rabbit anti-sheep IgG-heavy and light
chain specific; rabbit anti-goat IgG-heavy and
light chain specific; rabbit anti-bovine IgG-Fc
fragment specific; goat anti-human IgG-heavy
and light chain specific (Jackson Immunoresearch, West Grove, Pennsylvania, USA); goat
anti-bovine IgG-heavy chain specific; peroxidase-labeled protein A from Staphlococcus aureus (Kirkegaard and Perry Laboratories Inc.,
Gaithersburg, Maryland, USA); goat anti-canine IgG (Crawley Down, Sussex, UK); swine
anti-goat IgG (Boehringer Manheim Biochemicals, Indianapolis, Indiana, USA); sheep antibovine IgG1; and sheep anti-bovine IgG2 (The
Binding Site, Birmingham, UK). Based on this
preliminary work, rabbit anti-goat IgG-heavy
and light chain specific was selected as the secondary antibody because it demonstrated the
strongest immunoreactivity to elk sera.
The procedure for conducting the dot-blot
assay was as follows. Brucella abortus strain
RB51 was grown on tryptose agar (Difco Laboratories, Detroit, Michigan, USA) containing
5% bovine serum for 48 hr at 37 C. Bacteria
were removed from the agar by aspiration using saline, killed by irradiation (1.4 ⫻ 106 rads),
washed in saline, and stored in 1 ml aliquots at
⫺70 C. Antigen stock solutions for the assay
were made by spectrophotometric adjustment
of killed strain RB51 to 20% transmission at
600 nm. Thirty l of the appropriate suspension was added to each well of a 96-well microfiltration unit (Bio-Rad Laboratories, Richmond, California, USA) containing a nitrocellulose membrane (Schleicher and Schuell, Inc.)
with a pore size of 0.45 m. The membrane
was dried by applying a vacuum after 30 min
incubation at 20–22 C (room temperature).
Each well then received 100 l of 0.02M Tris,
0.5M NaCl buffer (Tris-NaCl, pH 7.5) containing 0.25% fish gelatin (Tris-FG, Norland Laboratory, New Brunswick, New Jersey, USA). After 30 min incubation, the nitrocellulose was
dried and washed twice by vacuum filtration
using 100 l of Tris-NaCl containing 0.3%
Tween 20 (Tris-NaCl-Tween, Sigma Chemical
Co, St. Louis, Missouri, USA). Ten-fold dilutions of serum samples were prepared in TrisFG beginning at a 1:20 dilution. Serum from
goats vaccinated with Brucella melitensis strain
16M served as positive controls for each assay.
Goat serum was used because there was no
source for a secondary antibody against elk
IgG. Several commercial secondary antibodies
were screened to identify which had the strongest cross-reaction with elk antibodies. Because
the secondary antibody selected for use was a
rabbit anti-goat IgG peroxidase conjugate, goat
serum was the ideal positive control. Goat serum against B. melintensis, obtained from pre-
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TABLE 1. Results of pregnant elk vaccinated with Brucella abortus strain RB51 on February 26, 1998 then
challenged on 7 April 1998 with B. abortus strain 2308. Antibodies against strain RB51 were measured in
cows at time of challenge; antibodies against strain 2308 were measured in cows at time of birth/abortion.
Culture statusb

Group

Strain RB51
antibody titera

Strain 2308
antibody titera

Abortions

Live births

Fetusc

Vaginac

Vaccinated
Control

7/7
0/7

5/7
7/7

5/7
7/7

2/7
0/7

2/4
5/5

4/6
6/6

Strain RB51 antibody titer positive if ⱖ1:640 as measured by dot blot assay; 2308 antibody titer positive based on the criteria
of Morton et al. (1981).
b Not all fetal or vaginal cultures analyzed due to sample contamination.
c Cultures from vaccinated elk were both strains RB51 and 2308; cultures from control elk were strain 2308.
a

RESULTS

No morbidity was observed from the
time of vaccination to challenge. Antibody
titers to strain RB51 were significantly
higher (P ⫽ 0.00004) in vaccinated elk
(8,533 ⫾ 1,080) compared to controls (125
⫾ 34). None of the control elk had strain
RB51 antibody titers ⬎1:160, whereas all
the vaccinated elk had titers ⱖ1:640. Several of the vaccinated elk and all of the
control elk seroconverted to strain 2308 af-

ter challenge (Table 1). The first abortion
occurred on 15 May 1998 (77 days postvaccination; 38 days postchallenge) from a
vaccinated elk. Ten aborted fetuses were
collected between 15 May and 26 June.
One fetus from each group was never
found and was presumed to have been
aborted based on vaginal examination and
consumed by the cow.
Sample sizes were sufficient to detect
relatively large (⬎50%) reductions in abortion rates among vaccinated elk (1 ⫺ ␤ ⱖ
0.43, where abortion rates for controls
were ⱖ0.86). Two of seven elk from the
vaccinated group and none of the elk from
the control group gave birth to viable
calves. Vaccination did not lower abortion
rates (P ⫽ 0.23). No Brucella spp. were
cultured from either viable calf, but one
calf had antibodies against strain 2308.
Neither calf had antibodies against strain
RB51.
Strains RB51 and 2308 were cultured
from two aborted fetuses from vaccinated
elk; no cultures were obtained from the
other two fetuses due to contamination.
Strain 2308 was cultured from five fetuses
from the control elk; one fetus was contaminated. Strains RB51 and 2308 were
also cultured in vaginal swabs from the
vaccinated group whereas cultures from
the control group were only strain 2308
(Table 1). Milk samples were obtained
from only three of the vaccinated elk and
none of the control elk; strain 2308 was
cultured from one milk sample.
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bacitracin, 1,800 I.U. polymixin B, 30-mg cyclohexamide, and 0.000125% crystal violet per
liter. Culture swabs were streaked across the
entire plate in one direction, then streaked at
right angles again covering the entire plate.
Plates were inverted and incubated at 37 C under 10% CO2, for a minimum of 6 days. Suspect bacterial colonies were removed and
streaked for isolation on Columbia blood agar
with 5% sheep blood (Hardy Diagnostics, Santa
Maria, California, USA) and MacConkey agar
plates (Hardy Diagnostics, Santa Maria, California, USA). Isolates which were unable to
grow on MacConkey agar were then identified
using standard bacteriological methods (Quinn
et al., 1994) and any Brucella sp. were differentiated by carbon utilization panels (Biolog,
Inc., Hayward, California, USA).
The null hypothesis tested was that vaccination with B. abortus strain RB51 does not protect against abortion in elk challenged with virulent strain 2308. Differences in abortion rates
between vaccinated and control groups were
compared by one-sided Fisher’s exact test for
two proportions at a significance level of alpha
ⱕ0.1. Antibody titers to strain RB51 vaccine
were compared by one-way ANOVA at a significance level of P ⱕ 0.05. Means are reported
with standard errors.

KREEGER ET AL.—RB51 VACCINE IN ELK

DISCUSSION

and Carter, 1950). Although the challenge
dose used in this study was reasonable, it
resulted in 100% of control elk aborting as
it did in previous studies (W. Cook, unpubl. data). It could be argued that a challenge dose causing consistent 100% abortion rates in unprotected animals is higher
than seen in natural infections. If true, the
challenge dose could have been unrealistic
and strain RB51 protection from abortion
could have been greater if a lower challenge dose had been used.
Protection from infection and elimination of B. abortus most likely requires
CMI responses (Nicoletti and Winter,
1990). The temporal development of CMI
in elk has not been examined. In cattle, it
took 10 to 12 wk after vaccination with
strain RB51 for lymph node cells to proliferate when incubated with strain 2308
(Stevens et al., 1995). This delay in proliferative response could have been due to
vaccine-induced lymphocyte depletion
(Araya et al., 1989). Thus, it is possible that
in the 40 days that elapsed between vaccination and challenge in this study, insufficient CMI responses had developed in
elk to prevent infection. If true, vaccination in the field would have to be conducted earlier than current practices in order to develop adequate CMI.
We could be left to conclude that strain
RB51 is simply not efficacious in elk. In
our study, RB51 vaccine was 28% (2/7) effective in preventing abortions. If this level
of protection was truly characteristic of
strain RB51 vaccine in pregnant elk, this
relatively low level may be beneficial from
a disease management viewpoint. A recently-developed, individual-based, stochastic model indicated that this level of
vaccine efficacy would still result in a decline in population seroprevalence over
time (Gross et al., 1998). A decline in seroprevalence would indicate fewer infected animals which would have fewer Brucella-induced abortions and, thus, a decreased likelihood of disease transmission.
This type of study needs to be repeated
and expanded. More time needs to be al-
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Elk vaccinated as calves with strain
RB51 and then challenged with the same
dose of strain 2308 used in this study
mostly aborted 6 to 8 wk after challenge
(W. Cook, unpubl. data). The first abortion
in our study did not occur until 11 wk
postvaccination. This longer period to
abortion could have been a function of the
lower pathogenicity of strain RB51. Culture of the fetus was inconclusive because
of contamination. However, the dam had
not seroconverted to strain 2308. Subsequent abortions in the vaccinated group
had mixed RB51 and 2308 cultures. Thus,
abortion strictly due to strain RB51 vaccination cannot be ruled out.
Strain RB51 vaccine did not provide significant protection from abortion following
challenge. Abortion occurred in all control
elk and in five of seven vaccinated elk 5 to
12 wk postchallenge. A previous study of
elk vaccinated as calves with 1 ⫻ 109 CFU
strain RB51 and then challenged when
pregnant also failed to demonstrate significant protection (W. Cook, unpubl. data).
Reasons for lack of protection in our study
could be due to (1) insufficient vaccine; (2)
excessive challenge dose; (3) insufficient
time between vaccination and challenge
for cell-mediated immunity (CMI) to develop; or (4) lack of strain RB51 efficacy
in elk.
The vaccine dose used in this study was
the same efficacious dose used in cattle
calves (Cheville et al., 1996). It was believed that any higher dose would increase
the risk of vaccine-induced abortions. Because vaccinated elk had antibody titers to
strain RB51, it was unlikely that the lack
of protection from abortion was due to an
insufficient vaccine dose.
The challenge dose was also chosen to
provide comparative data with previous
cattle and elk trials (McEwen et al., 1939;
Manthei and Carter, 1950; W. Cook, unpubl. data). In cattle trials, challenge with
ⱖ1.0 ⫻ 107 CFU strain 2308 generally resulted in 90–100% abortion rates (Manthei
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lowed between vaccination and challenge
to allow for development of CMI. If more
time proves beneficial, then this time period would have to be incorporated into
any field application. Also, increased vaccine dosages or multiple vaccinations need
to be assessed.
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